In what aspects does Retatrutid show its effects?
Retatrutid exhibits significant effects in multiple aspects
Significant weight loss effect: Retatrutid has demonstrated significant weight loss effects in multiple clinical trials. For example, in a clinical study involving 338 adults (Jastreboff A M M, 2023), patients treated with different doses of Retatrutid experienced significant weight loss at 48 weeks. Among them, patients in the 12mg dose group lost 24.2% of their body weight, and a high proportion of patients achieved weight loss to varying degrees. For instance, among patients receiving 4mg, 8mg, and 12mg doses, 92%, 100%, and 100% of the patients, respectively, lost 5% or more of their body weight. In another study [3], two randomized controlled trials involving 353 patients with type 2 diabetes mellitus showed that compared with the placebo, Retatrutid could significantly reduce the body weight of patients by 11.89kg, and also reduce glycated hemoglobin (HbA1C). In addition, in trials of adult patients with obesity without diabetes, Retatrutid caused a 24.2% weight loss in patients, and 83% of the patients lost 15% or more of their body weight at 48 weeks. These results indicate that Retatrutid has great potential in weight loss.
Treatment of type 2 diabetes mellitus: Retatrutid also shows certain potential in the treatment of type 2 diabetes mellitus. In some clinical trials, Retatrutid has shown a reduction in glycated hemoglobin (HbA1c) and dose-dependent weight loss. For example, in one study, in patients with type 2 diabetes mellitus, Retatrutid demonstrated significant blood glucose control effects. Compared with the placebo, glycated hemoglobin decreased by 1.64% [3]. Additionally, in a randomized, double-blind, placebo and active-controlled parallel-group phase 2 trial, animal models with type 2 diabetes mellitus, after receiving Retatrutid treatment, showed a significant decrease in glycated hemoglobin levels, and their body weight also decreased in a dose-dependent manner [4]. This can be attributed to the comprehensive effects of the drug on GLP-1, GCGR, and GIPR, which improve glucose metabolism and energy balance.
Improvement of cardiovascular risk factors: Retatrutid can not only reduce body weight but also improve cardiovascular risk factors, such as the serum lipid profile and glycated hemoglobin levels. This indicates a close pathophysiological link between obesity and cardiovascular diseases, and Retatrutid may improve the cardiovascular health of obese patients through multiple pathways. For example, reducing non-HDL-C, apoB, and LDLP levels can reduce the risk of atherosclerosis; reducing glycated hemoglobin levels can improve blood glucose control in patients with diabetes, thereby reducing the risk of cardiovascular complications [3, 5, 6].
Treatment of non-alcoholic fatty liver disease (NAFLD): Retatrutid is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Studies have shown that Retatrutid has the potential to treat non-alcoholic fatty liver disease. In one study, a randomized, double-blind, placebo-controlled trial was conducted for 48 weeks on participants with metabolic dysfunction-associated fatty liver disease and a liver fat content of ≥10%. The results showed that at 24 weeks, the average relative changes in liver fat from the baseline in participants treated with different doses of Retatrutid (1mg, 4mg, 8mg, and 12mg) were -42.9%, -57.0%, -81.4%, and -82.4%, respectively, while that in the placebo group was +0.3%[7]. This indicates that Retatrutid may have a significant therapeutic effect on non-alcoholic fatty liver disease.
In conclusion, as a novel triple receptor agonist, Retatrutid shows great potential in the treatment of obesity and related diseases. It can regulate human metabolism from multiple dimensions by activating the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor, improving blood glucose control, reducing body weight, and regulating lipid metabolism. The emergence of Retatrutid has brought new treatment options for patients with obesity, type 2 diabetes mellitus, etc. It is expected to break through the limitations of traditional single receptor agonist drugs, provide a more powerful weapon for solving the increasingly serious problems of obesity and metabolic diseases, promote the further development of related medical fields, improve the quality of life of patients, and reduce the social medical burden.
Scientific Journal Author
Rosenstock J is a highly influential scholar in the medical field, closely collaborating with institutions such as the University of Texas Southwestern Medical Center and the University of Texas Dallas. He also conducts research at centers like the Canadian VIGOUR Center and Veloc Clin Res Ctr Med City.
His research spans endocrinology and metabolism, cardiovascular system and cardiology, pharmacology, and experimental medicine, with a focus on diabetes, obesity, and related treatments and drug development. J Rosenstock has achieved significant success in clinical medicine, being named a Highly Cited Researcher from 2017 to 2024. This highlights the high impact and broad recognition of his work. Through collaboration with multiple research institutions, he has successfully translated basic research findings into clinical applications, benefiting patients with metabolic and cardiovascular diseases and advancing medical science. Rosenstock J is listed in the reference of citation [4].
Reviews
There are no reviews yet.